Edition:
United Kingdom

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

11.00USD
20 Apr 2018
Change (% chg)

$0.15 (+1.38%)
Prev Close
$10.85
Open
$10.78
Day's High
$11.01
Day's Low
$10.78
Volume
12,949
Avg. Vol
--
52-wk High
$33.72
52-wk Low
$6.83

Chart for

About

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies... (more)

Overall

No Ratios Available.

Financials

  SLDB.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -- -- --
ROI: -- 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

* SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY

18 Apr 2018

BRIEF-Solid Biosciences Reports Full Year 2017 Financial Results And Provides Corporate Update

* SOLID BIOSCIENCES REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

29 Mar 2018

BRIEF-Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial

* SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY

14 Mar 2018

BRIEF-Solid Biosciences Says Now Sees IPO Of 7 Mln Shares Of Common Stock Priced Between $18-$19/Shr - SEC Filing

* SOLID BIOSCIENCES LLC SAYS NOW SEES IPO OF 7.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $18.00 AND $19.00 PER SHARE - SEC FILING

24 Jan 2018

Earnings vs. Estimates